PLUS THERAPEUTICS, INC. Operating Income Loss

• PLUS THERAPEUTICS, INC. showed a decrease of -4.1% in Operating Income Loss from 2024 to 2025.
• This data is from PLUS THERAPEUTICS, INC.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
• XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Quarterly values from 10-Q filings: Q2 2010: -$5.04 million | Q3 2010: -$9.59 million | Q1 2011: -$11.24 million | Q2 2011: -$4.37 million | Q3 2011: -$7.82 million | Q1 2012: -$8.37 million | Q2 2012: -$6.96 million | Q3 2012: -$10.33 million | Q1 2013: -$6.74 million | Q2 2013: -$6.36 million | Q3 2013: -$8.46 million | Q1 2014: -$9.55 million | Q2 2014: -$10.69 million | Q3 2014: -$7.89 million | Q1 2015: -$21.00 million | Q2 2015: $5.79 million | Q3 2015: $2.00 million | Q1 2016: -$5.10 million | Q2 2016: -$6.22 million | Q3 2016: -$4.80 million | Q1 2017: -$7.13 million | Q2 2017: -$5.58 million | Q3 2017: -$4.34 million | Q1 2018: -$4.35 million | Q2 2018: -$1.85 million | Q3 2018: -$2.23 million | Q1 2019: -$2.17 million | Q2 2019: -$1.96 million | Q3 2019: $2.68 million | Q1 2020: -$2.44 million | Q2 2020: -$2.35 million | Q3 2020: -$1.40 million | Q1 2021: -$2.48 million | Q2 2021: -$2.58 million | Q3 2021: -$3.50 million | Q1 2022: -$3.93 million | Q2 2022: -$5.12 million | Q3 2022: -$5.09 million | Q1 2023: -$4.72 million | Q2 2023: -$1.49 million | Q3 2023: -$3.25 million | Q1 2024: -$3.30 million | Q2 2024: -$3.70 million | Q3 2024: -$3.80 million | Q1 2025: -$3.54 million | Q2 2025: -$1.54 million | Q3 2025: -$4.48 million.
• Over the full 17 years of available data (2009 to 2025), PLUS THERAPEUTICS, INC.'s Operating Income Loss has grown by 29.0%.
• Historical annual values: Fiscal year 2025: -$15.30 million | Fiscal year 2024: -$14.70 million | Fiscal year 2023: -$13.32 million | Fiscal year 2022: -$19.71 million | Fiscal year 2021: -$12.49 million | Fiscal year 2020: -$9.58 million | Fiscal year 2019: -$3.66 million | Fiscal year 2018: -$8.76 million | Fiscal year 2017: -$20.68 million | Fiscal year 2016: -$19.71 million | Fiscal year 2015: -$15.29 million | Fiscal year 2014: -$32.44 million | Fiscal year 2013: -$30.68 million | Fiscal year 2012: -$28.42 million | Fiscal year 2011: -$29.41 million | Fiscal year 2010: -$25.32 million | Fiscal year 2009: -$21.55 million.
• Data sourced from SEC EDGAR public filings as of August 8, 2026.

Last verified: August 8, 2026